STERIS (NYSE:STE) Releases Earnings Results, Misses Estimates By $0.01 EPS

STERIS (NYSE:STE) released its quarterly earnings data on Wednesday. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01), Zacks reports. STERIS had a net margin of 8.02% and a return on equity of 13.78%.

STERIS Price Performance

NYSE STE traded up $1.57 on Wednesday, reaching $220.97. The company’s stock had a trading volume of 886,684 shares, compared to its average volume of 476,576. STERIS has a 52 week low of $197.82 and a 52 week high of $248.24. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The firm has a market cap of $21.81 billion, a PE ratio of 50.45 and a beta of 0.84. The business has a 50-day moving average price of $212.26 and a 200 day moving average price of $224.61.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.03%. STERIS’s dividend payout ratio is currently 52.05%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Monday, November 18th. StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Stephens reaffirmed an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Thursday, November 7th. Finally, Piper Sandler raised their target price on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $263.75.

Insiders Place Their Bets

In related news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.